论文部分内容阅读
随着越来越多的生物标记物走向成熟,将来就可以挑选出哪些患者会对治疗有反应,哪些患者对治疗没反应,而不必让患者的时间浪费在无效的治疗上。
As more and more biomarkers mature, one can pick which patients will respond to the treatment and which patients will not respond to the treatment, without having to waste the patient’s time on ineffective treatment.